Niapelf (Paliperidone)

Paliperidone, the active ingredient in Niapelf, is a atypical antipsychotic presented as a intramuscular injection for intramuscular use. It treats schizophrenia and schizoaffective disorder in adult patients. GNH USA supplies Niapelf as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Paliperidone acts on dopamine and serotonin pathways to manage psychotic disorders. - Schizophrenia: reduces psychotic symptoms and lowers relapse risk. - Schizoaffective disorder: stabilises mood swings and psychosis. - Maintenance treatment of schizophrenia: provides long‑acting control of symptoms.

Common Side Effects: - Weight gain: increase in body mass observed in some patients. - Sedation: drowsiness or feeling of tiredness. - Dizziness: light‑headed sensation, especially on standing. - Headache: mild to moderate cranial pain. - Injection site pain: discomfort at the intramuscular site. - Increased prolactin: hormonal changes leading to menstrual or sexual disturbances.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: life‑threatening reaction with fever and muscle rigidity. - Tardive dyskinesia: involuntary, repetitive movements. - Agranulocytosis: severe drop in white blood cells. - Severe hypotension: marked drop in blood pressure. - Myocarditis: inflammation of heart muscle. - Seizures: convulsive episodes.

Before initiating therapy, clinicians should consider several safety aspects. - Metabolic monitoring: regularly assess weight, glucose and lipid levels. - Cardiovascular assessment: evaluate blood pressure and heart function. - Orthostatic hypotension: monitor for dizziness on standing. - Prolactin effects: watch for menstrual irregularities or galactorrhea. - Hepatic impairment: adjust use in patients with liver dysfunction. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Paliperidone may interact with other medicines, requiring careful management. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase paliperidone levels. - Strong CYP3A4 inducers (e.g., rifampin): reduce efficacy. - Other dopamine antagonists: additive antipsychotic effects. - QT‑prolonging agents: risk of cardiac arrhythmia. - CNS depressants: enhanced sedation. Moderate Interactions (Monitor Closely): - Antihypertensives: possible additive blood‑pressure lowering. - Anticholinergics and antihistamines: may increase anticholinergic burden.